Travere Therapeutics (TVTX) Share-based Compensation (2013 - 2026)

Travere Therapeutics has reported Share-based Compensation for 14 years, with the latest figure at $16.1 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 40.5% year-over-year to $16.1 million; the trailing twelve-month figure through Mar 2026 stood at $49.5 million (up 28.14% YoY), and the FY2025 full-year result was $44.9 million, up 21.55% from the prior year.
• Share-based Compensation for Q1 2026 stood at $16.1 million, up from $11.5 million in the prior quarter.
• The five-year high for Share-based Compensation was $16.1 million in Q1 2026, with the low at $8.0 million in Q3 2024.
• Historically, Share-based Compensation has averaged $10.6 million across 5 years, with a median of $10.6 million in 2025.
• Annual changes were most pronounced in 2022 — Share-based Compensation surged 73.2% — and 2024, when it decreased 29.14%.
• Travere Therapeutics' Share-based Compensation stood at $9.3 million in 2022, then declined by 12.4% to $8.1 million in 2023, then gained by 13.14% to $9.2 million in 2024, then increased by 24.42% to $11.5 million in 2025, then soared by 40.84% to $16.1 million in 2026.
• The last three Share-based Compensation figures came in at $16.1 million (Q1 2026), $11.5 million (Q4 2025), and $11.3 million (Q3 2025), per Business Quant data.